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Human papillomavirus type 18 is a causative agent of epithelial cancers in the uterine cervix. We show here that estrogen
and progesterone activate -galactosidase expression from the early promoter of this virus in the genital epithelia of
transgenic mice. Ovariectomy caused suppression of transgene expression exclusively in vagina and cervix epithelia.
-Galactosidase expression could be restored in ovariectomized females by administration of estrogen, alone or in
combination with progesterone. Further, rescue of transgene expression was inhibited by the estrogen antagonist tamoxifenINTRODUCTION
Human papillomaviruses (HPVs) comprise a group of
over 100 virus genotypes associated with epithelial neo-
plasias of skin and mucosae (zur Hausen and de Villiers,
1994). A subset of genital HPV types known as “high-risk”
or oncogenic HPVs is associated with cancer of the
uterine cervix, the second most common malignancy in
women worldwide. Of these, HPV types 16 and 18 are the
most prevalent. High-risk HPVs encode two early pro-
teins with transforming properties, E6 and E7 (zur
Hausen, 1996), that are consistently expressed in 80–
90% of cervical neoplasias and in tumor-derived cell
lines, such as HeLa (HPV-18). Transcription of E6 and E7
is driven by a long control region (LCR) which contains
elements for binding of viral and cellular transcription
factors (Garcia-Carranca et al., 1988). The major viral
transcription factor, E2, is frequently disrupted in cervical
carcinomas (Schwarz et al., 1985). Thus, in tumor cells
the HPV LCR is thought to be regulated exclusively by
cellular factors, including receptors of steroid hormones
(glucocorticoid, estrogen, and progesterone) (Chan et al.,
1989; Mitrani-Rosenbaum et al., 1989; reviewed in Pater
et al., 1994). Accordingly, epidemiological surveys indi-
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and pregnancy, which involve elevated levels of circulat-
ing estrogen and progesterone, increase the risk for
developing invasive cervical carcinomas among women
with HPV-positive cervical lesions (Brinton et al., 1986,
1989; Herrero et al., 1990; Hildesheim et al., 1990).
The study of the mechanisms underlying regulation of
HPV expression in vivo has been complicated by the
strict species-specificity of these viruses. We have gen-
erated a transgenic mouse model in which a -galacto-
sidase gene is expressed under control of the HPV-18
LCR (Cid et al., 1993). Characterization of expression in
three different transgenic lines showed the highest lev-
els of reporter in vagina–cervix and tongue stratified
epithelia. Therefore, these mice offer a model in which
regulation of the HPV-18 LCR promoter can be studied in
vivo. In this study we have extended the analysis of our
transgenic mice to determine the effect of estrogen and
progesterone on the HPV-18 LCR by quantifying reporter
expression under various physiological and pharmaco-
logical conditions.
RESULTS AND DISCUSSION
Enhanced activity of the HPV-18-LCR-lacZ transgene
during pregnancy
Epidemiological studies have shown that pregnancy
accelerates progression of preexisting cervical cancers
and that parity is a risk factor for this disease (Brinton et
al., 1989). A possible explanation for this phenomenonand the anti-progesterone RU486, suggesting that this was
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oncogenes in infected lesions during pregnancy. This
would imply that estrogens and/or progesterone, the
levels in serum of which remain physiologically in-
creased during pregnancy, may stimulate HPV early
gene expression, either directly upon activation of their
cognate receptors or by indirect, more complex mecha-
nisms. Indeed, these hormones have been shown to
enhance the transforming capability of high-risk HPVs in
vitro (see Pater et al., 1994, and references therein).
We have investigated reporter expression during preg-
nancy in HPV-18-LCR-lacZ transgenic mice, which harbor
an HPV-18 LCR fused to the Escherichia coli lacZ gene
and SV40 poly(A) sequences (Cid et al., 1993). Three
different lines displayed a consistent expression pattern
of the transgene, mainly restricted to the stratified epi-
thelia of tongue (males and females) and vagina–cervix
(females). Two of these lines, Nos. 406 and 411, showing
higher levels of transgene expression were chosen for
this study.
-Galactosidase activity was measured at different
stages of pregnancy (1, 7, and 19 days postcoitus) and
shortly after delivery using protein extracts of crude ho-
mogenates prepared from vagina–cervix or tongue of
transgenic females and nontransgenic littermates. As
shown in Fig. 1A, a trend toward increasing reporter
activity was observed in genital epithelia during preg-
nancy. This increase correlated with ascent levels of
circulating estrogen and progesterone, which reached a
peak toward the last week of pregnancy (Casey et al.,
1992; Rugh, 1990). In contrast, no significant variation
was observed in the epithelium of the tongue (Fig. 1A).
The activity of the HPV-18-LCR-lacZ transgene during
the estrous cycle follows the fluctuations of
circulating estrogen and progesterone
During the estrous cycle, mature ovarian follicles se-
crete progesterone and estrogen in response to gonad-
otropins. Circulating levels of both hormones reach a
maximum at the proestrous–estrous phase. In order to
evaluate the effect of such fluctuation on the HPV-18 LCR
promoter, groups of transgenic females synchronized at
any phase of the estrous cycle (diestrus, proestrus, es-
trus, or metestrus) were used to quantify reporter activity
in their vagina–cervix epithelia. The time of estrous
phase was assessed by microscopic examination of
vaginal smears for the presence of characteristic cell
types (Cunliffe-Beamer and Les, 1987).
FIG. 1. Influence of pregnancy and the estrous cycle on HPV-18-LCR-lacZ transgene expression in vagina–cervix and tongue epithelia. Transgenic
females heterozygous for HPV-18-LCR-lacZ were sacrificed when indicated, and tissue samples were removed for analysis of reporter expression.
-Galactosidase assays were performed with 0.2 mg of total protein. Crude extracts of protein were from vagina–cervix and tongue epithelia of
transgenic animals and vagina–cervix epithelia of nontransgenic littermates. Endogenous galactosidase activities in the tongues of nontransgenic
controls were negligible and are not shown. Symbol plots correspond to mean values  SE of biochemical analysis of 6–8 mice each. Typical
gestation time was 20 days. Plots (relative values) of serum levels of estradiol (dashed lines) and progesterone (continuous fine lines) during
pregnancy and the estrous cycle have been drawn according to Freeman (1988). Peak values, obtained by RIA as described previously (Freeman,
1988; Goodman, 1978), were, for estrogen, 30 pg/ml (day 19 of gestation) and 50 pg/ml (proestrus–estrus), and, for progesterone, 70 ng/ml (day 14
of gestation) and 20 ng/ml (estrus). (A) Transgene expression during pregnancy. Transgenic (heterozygous) females were crossed with nontransgenic
males and sacrificed 1, 7, and 19 days postcoitus and two days after delivery (2 a.d.) for quantitative analysis of -galactosidase activity. (B) Transgene
expression during the estrous cycle. Females were sacrificed in the morning of the day of the indicated phase: D, diestrus; P, proestrus; E, estrus;
M, metestrus.
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We observed an increased -galactosidase expres-
sion in the genital epithelia of the HPV-18-LCR-lacZ that
correlated with higher levels of circulating estrogens and
progesterone. As shown in Fig. 1B, activity was maximal
at estrus, shortly after the levels of estrogens and pro-
gesterone reached a peak, suggesting that these hor-
mones might account for the activation of the HPV-18
LCR. Histochemical analysis of -galactosidase activity
in thin sections and whole mounts of vagina–cervix tis-
sues further confirmed this observation (Fig. 2). A stain-
ing of high intensity was seen at estrus (Figs. 2A and 2C),
which was localized to the suprabasal layers of the
vaginal epidermis and the columnar endocervical epithe-
lia, especially the metaplasia of the transformation zone.
This is consistent with the predisposition of HPV to infect
and form lesions in these areas of the human uterus. In
contrast, almost no staining could be detected at
diestrus (Figs. 2B and 2D). Quantitative analysis of -ga-
lactosidase activity in the tongue epithelium of the same
animals showed no significant variation during the es-
trous cycle (Fig. 1B).
Ovariectomy causes suppression of HPV-18-LCR-lacZ
activity in a tissue-specific manner
The effect of ovarian estrogens and progesterone on
the HPV-18 early promoter was confirmed in ovariecto-
mized animals. Transgenic females (4–6 weeks old)
were ovariectomized and reporter activity was measured
in their genital epithelia 3 weeks later, when concentra-
tions of ovarian steroids in blood and of their receptors in
target tissues are rather low (Freeman, 1988; Leavitt et
al., 1974; Parczyk et al., 1997). As illustrated in Fig. 3,
ovariectomized females (Ovx) exhibited very low reporter
activity in their vaginal epithelium, only slightly higher
than that of nontransgenic animals. Ovariectomy did not
affect transgene activity in the tongue epithelium (Fig. 3),
as could be expected, since this tissue does not express
estrogen or progesterone receptors (Yamashita, 2001).
These data support a role for estrogen and progesterone
hormones released by the ovary in regulating the HPV-18
promoter in a tissue-specific manner.
Effects of exogenous 17-estradiol, progesterone,
and their antagonists on HPV-18-LCR-lacZ activity in
ovariectomized, transgenic females
The inhibitory effect of ovariectomy on -gal activity
prompted us to attempt the rescue of reporter expression
by administration of estrogen and progesterone to ovari-
ectomized animals. Groups of transgenic females were
ovariectomized and allowed to recover, and their endog-
enous hormone levels were given time to stabilize for at
least 3 weeks, a time when progesterone receptor (PR)
FIG. 3. Effects of estrogen, progesterone, and their antagonists
tamoxifen and RU486 on HPV-18-LCR-lacZ activity in vagina–cervix and
tongue epithelia. Ovariectomized animals (transgenic females and non-
transgenic littermates) were either not treated (Ovx) or injected with
17-estradiol (E2), E2 followed by progesterone (E2  Pg), E2 and
tamoxifen (E2  Tx), E2 followed by progesterone and RU486 (E2 
Pg  RU), E2 and RU486 (E2  RU), or as described in the text. The
mice were sacrificed 1 day after hormone administration. Quantitative
analysis of -galactosidase activity was performed with 200 g of
protein of crude extracts of vagina–cervix and tongue as described
under Materials and Methods. -Galactosidase activities in ovariecto-
mized transgenic and nontransgenic mice injected with vehicle without
hormone were comparable to those of untreated animals (Ovx) and are
not shown.
FIG. 2. Histochemical staining of -galactosdase in vagina and
cervix epithelia of HPV-18-LCR-lacZ transgenic females during the
estrous cycle. Heterozygous transgenic females (2–3 months old) were
sacrificed in the morning at the estrus and diestrus phases of the
estrous cycle, as determined by microscopic examination of vaginal
smears. Vagina and cervix tissues were dissected, fixed for 2 h with 4%
paraformaldehyde, embedded in 30% sucrose in PBS, and snap frozen
for cryosectioning (7-m thick sections; A and B). Alternatively, whole
mounts of vagina–cervix (C and D) were stained using X-Gal substrate,
which is cleaved by the -galactosidase to yield blue insoluble indigo.
(A and C) Estrus and (B and D) diestrus. Bar, 60 m (A and B) and 0.7
mm (C and D).
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decays to a minimum (Graham and Clarke, 1997). The
animals were then treated with estrogen, progesterone,
or a combination of both hormones before being sacri-
ficed for quantification of -galactosidase activity in vagi-
na–cervix and tongue epithelia.
As shown in Fig. 3 (column E2), E2 administration
sufficed to restore transgene activity in the genital tract
up to the levels found in nonovariectomized females at
the proestrous–estrous phase (compare to Fig. 1B). Two
more groups of mice, in which E2 treatment was re-
peated once or twice with a 3-day interval, showed
reporter activities comparable to those of the group
treated only once (data not shown), indicating that the
hormone was able to maintain reporter expression to
high levels for longer periods. Transgene expression in
the epithelium of the tongue was not affected by the E2
treatment. These results are in agreement with the acti-
vation of the HPV-18 LCR by estrogen in cells expressing
estrogen receptors.
Although the HPV-18 LCR contains a progesterone
responsive element, and progesterone activates HPV-18
transcription in vitro (Chan et al., 1989), in our transgenic
model administration of progesterone to a group of ovari-
ectomized animals without previous injection of E2 had a
weak effect on reporter expression (Fig. 3). This is not
surprising, since ovariectomy reduces PR levels in target
cells due to a decrease in circulating estrogens, which
are needed to maintain PR expression (Baumann et al.,
1999; Leavitt et al., 1974; Tsai and O’Malle, 1994). There-
fore, in a third group, previous to progesterone adminis-
tration PR expression was induced by E2 treatment as
described above. On the third day, these mice were
injected once with 500 g progesterone. One day later,
the mice were sacrificed and reporter expression was
quantified. As shown in Fig. 3, this group (column E2 
Pg) showed a recovery of reporter activity in their vagina–
cervix epithelia slightly higher than that obtained by
administration of E2 alone (column E2). Control trans-
genic females, ovariectomized and injected as described
above but with vehicle without any hormone, displayed
no change in reporter activity (data not shown). A possi-
ble explanation for the fact that little synergistic effect of
the two hormones was obtained may be that E2 suffices
to activate the HPV-18 early promoter to an extent be-
yond which progesterone has little effect, or that there is
inhibitory cross-talk between receptors (Kraus et al.,
1995).
We next tested whether, as may be expected if the
effect of E2 were specific, the estrogen antagonist tamox-
ifen prevented rescue of reporter activity by E2 in ovari-
ectomized animals. An excess of tamoxifen injected
along with E2 reduced recovery of reporter activity to
about 50% of that observed with E2 alone (Fig. 3, E2 
Tx). This observation suggests that the estrogen receptor
is able to induce activation of the HPV early promoter in
vivo. Nevertheless, tamoxifen is a weak agonist, which
may account for the incomplete suppression (i.e., to the
Ovx levels) of -galactosidase expression in the vagina–
cervix of the E2-treated ovariectomized females. Simi-
larly, treatment of ovariectomized animals sequentially
with E2 and then with progesterone and a 10-fold excess
of the anti-progestin mifepristone (RU486) reduced acti-
vation of reporter activity to 40% of that obtained with
only E2 and progesterone (P  0.05) (Fig. 3, E2  Pg 
RU). This effect is in agreement with activation of trans-
gene expression by the PR. Furthermore, even lower
activation was observed when RU486 was administered
in combination with E2 (Fig. 3, E2  RU). This inhibition of
the E2 effect by RU486 may be explained by the anti-
estrogenic effect of this agent that involves the proges-
terone receptor (Kraus et al., 1995; McDonnell and Gold-
man, 1994). The above effects were tissue-specific, since
neither ovariectomy nor exogenous administration of es-
trogen, progesterone, or their antagonists had significant
effects on transgene expression in the tongue epithelium
(Fig. 3, white bars).
In a previous work using one of our transgenic lines,
Michelin et al. (1997) investigated the effect of proges-
terone administration on HPV-18-LCR-lacZ activity in
tongue epithelia of ovariectomized animals. These au-
thors reported a slight transient activation after 24 h,
which we were not able to see in any of the two lines
used in our study. This activation, however, was surpris-
ing, since progesterone receptors are not expressed in
the tongue. We have described previously a transient
activation of the HPV-18 LCR by the glucocorticoid dexa-
methasone in the tongue epithelium of these mice (Cid et
al., 1993), which is known to express glucocorticoid re-
ceptors (Abbott et al., 1994; Yamashita, 2001). As Mich-
elin et al. (1997) used for their experiments progeny
derived from a single homozygous transgenic male,
those results should be interpreted cautiously. In that
study, activity of the HPV-18-LCR-lacZ in genital epithelia
was not determined.
In summary, we show for the first time in vivo a tissue-
specific activation of the HPV-18 early promoter by E2
and progesterone, which can be inhibited by tamoxifen
and RU486. Because HPV carcinogenesis relies on ex-
pression of the viral early genes, factors influencing HPV
expression may be of critical importance in the develop-
ment of cervical carcinomas. Our data support the notion
that ovarian hormones could be one such factor and
suggest that sustained elevated serum levels of estro-
gen and/or progesterone, or increased expression of
their receptors in the cervical epithelium, could account
for an indirect mechanism of oncogenesis by activating
HPV early gene expression. Furthermore, these data
suggest that specific estrogen and progesterone antag-
onists, such as tamoxifen and RU486, may be useful for
repressing HPV-18 oncogene expression in cervical car-
cinomas.
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MATERIALS AND METHODS
Transgenic mice
HPV-18-LCR-lacZ transgenic mice were generated
from the hybrid strain C57B1/6J  C3HeB/FeJ by micro-
injection, into the pronuclei of one-cell embryos of the F1
generation, of a DNA fragment containing the HPV-18
LCR fused to an E. coli lacZ gene and an SV40 poly(A)
sequence (Cid et al., 1993). Two lines (Nos. 406 and 411)
used in this study were maintained by crossing back
transgenic progeny to nontransgenic mice (C57B1/6J 
C3HeB/FeJ). Nontransgenic littermate females were
used as controls.
Pregnancy and estrous cycle determination
Transgenic females were bred with (C57B1/6J 
C3H)F1 nontransgenic males. Pregnancy was confirmed
by the presence of a vaginal plug the following day,
which was designated as day 1 of pregnancy. The phase
of the estrous cycle in nonpregnant females was deter-
mined by microscopic examination of vaginal smears
(Cunliffe-Beamer and Les, 1987). For the measurements
of -galactosidase activity shown in Fig. 1, groups of 4–6
and 3–4 females (8–16 weeks old) of lines 406 and 411,
respectively, were used.
Ovariectomy and hormonal treatments
Transgenic females (10–16 weeks old) were surgically
ovariectomized. Three to five weeks later, they were
treated by subcutaneous injection on a daily basis with
E2 and progesterone, separately or in combination, or
with injection vehicle alone. A group was injected twice
(one dose per day) with E2 (17-estradiol, 15 g/day;
Sigma Chemical Co., St. Louis, MO) diluted in propylene
glycol and on the third day with the vehicle alone. An-
other group was injected twice with E2 as above and on
the third day with progesterone (500 g; Sigma) diluted
in propylene glycol. Similarly, a third group was injected
twice with E2 and then with progesterone plus an excess
of RU486 (5 mg; Roussel UCLAF–Hoetsch). A fourth
group was injected the first 2 days with E2 mixed with a
10-fold excess of tamoxifen (150 g; Sigma) and the third
day with vehicle. Finally, a last group was injected the
first 2 days with E2 mixed with RU486 (5 mg) and the third
day with vehicle. Animals were sacrificed on the morning
of the fourth day and tissue homogenates prepared for
-galactosidase activity measurements. Each group of
animals consisted of 4–6 and 3–4 ovariectomized fe-
males (8–16 weeks old) of lines 406 and 411, respectively.
-Galactosidase activity
Quantitative analysis of -galactosidase activity in
crude extracts was performed by the ONPG assay as
described elsewhere (Cid et al., 1993; Cid-Arregui et al.,
1998). In brief, 200–400 g of total protein extract was
incubated with 800 g of ONPG at 37°C for 1 h in PM-2
buffer (33 mM NaH2PO4, 66 mM Na2HPO4, 0.1 mM
MnCl2, 2 mM MgSO4, 40 mM -mercaptoethanol, pH 7.3)
to a final volume of 1 ml. Color development was mea-
sured at A420 against a blank without protein. -Galacto-
sidase-specific activities were calculated, after subtract-
ing the initial absorbance of the reaction, using the
formula units  380  A420/time (min), such that 1 unit is
equivalent to the conversion of 1 nmol of ONPG per min
at 37°C (Norton and Coffin, 1985). Histochemistry was
performed as described previously (Cid-Arregui et al.,
1998). Briefly, after fixation with 2% paraformaldehyde,
0.2% glutaraldehyde, 2 mM MgCl2, in PBS (pH 7.3) for 2 h,
organs were washed twice for 5 min at 4°C with 0.01%
sodium deoxycholate, 0.02% NP-40, 2 mM MgCl2, in PBS,
saturated with 30% sucrose, 2 mM MgCl2/PBS for 3 h at
4°C and frozen using isopentane/liquid N2. Sections
were refixed for 5 min at 4°C, washed for 10 min, stained
with X-Gal (1 mg/ml, 2 mM MgCl2, 0.01% sodium deoxy-
cholate, 0.02% NP-40, 5 mM potassium ferrocyanide, 5
mM potassium ferricyanide, in PBS) for 12 to 20 h at
37°C. For whole-organ staining, vaginas were dissected
and immediately fixed in 1% formaldehyde, 0.2% glutar-
aldehyde in PBS for 1 h at room temperature and then
washed 4–5 times in PBS. Staining was performed with
1 mg/ml of X-Gal in 0.01% sodium deoxycholate, 0.02%
NP-40 in PBS at 30°C for 6 h in the dark. Finally, a second
fixation was performed in 1% formaldehyde, 2% glutaral-
dehyde in PBS.
Statistical analyses
Differences in -galactosidase expression were ana-
lyzed by adjusted one-way ANOVA test with P values
corrected by the Bonferroni method on all groups of
treated mice.
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